首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties.
【24h】

Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties.

机译:释放一氧化氮(NO)的他汀类衍生物,一类药物显示出增强的抗增殖和抗炎特性。

获取原文
获取原文并翻译 | 示例
       

摘要

Inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, namely statins, exert pleiotropic actions beyond lipid-lowering effects. Their pharmacological activity on atherosclerotic plaque stability and vascular inflammation appears to be mediated, at least in part, by nitric oxide (NO). With the aim of enhancing the nonlipid-lowering properties of selected statins, we introduced a NO-releasing moiety into the structure of pravastatin (NCX 6550) and fluvastatin (NCX 6553). NO release was evaluated as nitrosylhemoglobin adduct formation by using EPR spectroscopy in rat blood. Both compounds produced a linear time-dependent increase in nitrosylhemoglobin formation, which is consistent with slow NO release kinetics. In PC12 cells, unlike their native statins, both compounds stimulated cGMP formation (NCX 6550, EC(50) = 2.3 +/- 0.2 microM; NCX 6553, EC(50) = 2.7 +/- 0.2 microM). Moreover, NCX 6550 potently inhibited cell proliferation in rat aortic smooth muscle cells (IC(50) = 2.2 +/- 0.3 microM) with a mechanism that involved both the polyamine and HMG-CoA reductase signaling pathways. Hence, mevalonate or putrescine partially reverted the effects of NCX 6550 and their combination was fully effective. In RAW 264.7 murine macrophage cells stimulated with lipopolysaccharide (1 microg/ml), NCX 6550, but not pravastatin, significantly decreased inducible NO synthase and cyclooxygenase-2 protein expression as well as nitrite accumulation. All together, the data show that the previously undescribed NO-releasing statins retain HMG-CoA reductase inhibitory activity and release bioactive NO slowly. Among the additional properties, compared with native statins, the NO-releasing statins show enhanced antiinflammatory effects. Thus, NO-releasing statins represent an interesting class of drugs having potential in the therapy of disorders associated with endothelial dysfunction and vascular inflammation.
机译:3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶的抑制剂,即他汀类药物,具有多效性作用,不仅具有降脂作用。它们对动脉粥样硬化斑块稳定性和血管炎症的药理活性似乎至少部分地由一氧化氮(NO)介导。为了增强所选他汀类药物的非降脂性能,我们在普伐他汀(NCX 6550)和氟伐他汀(NCX 6553)的结构中引入了NO释放部分。通过使用EPR光谱在大鼠血液中评估NO释放为亚硝酰基血红蛋白加合物的形成。两种化合物在亚硝酰基血红蛋白的形成上均呈线性时间依赖性,这与缓慢的NO释放动力学相符。在PC12细胞中,与它们的天然他汀类药物不同,这两种化合物都刺激cGMP的形成(NCX 6550,EC(50)= 2.3 +/- 0.2 microM; NCX 6553,EC(50)= 2.7 +/- 0.2 microM)。此外,NCX 6550具有涉及多胺和HMG-CoA还原酶信号通路的机制,可有效抑制大鼠主动脉平滑肌细胞的增殖(IC(50)= 2.2 +/- 0.3 microM)。因此,甲羟戊酸或腐胺可以部分恢复NCX 6550的作用,并且它们的组合完全有效。在脂多糖(1微克/毫升)刺激下的RAW 264.7鼠巨噬细胞中,NCX 6550而非普伐他汀可显着降低诱导型NO合酶和环氧合酶2蛋白的表达以及亚硝酸盐的积累。总之,数据表明先前未描述的NO释放他汀类药物保留了HMG-CoA还原酶抑制活性并缓慢释放生物活性NO。在其他特性中,与天然他汀类药物相比,释放NO的他汀类药物显示出增强的抗炎作用。因此,NO释放他汀类药物是一类有趣的药物,在治疗与内皮功能障碍和血管炎症相关的疾病中具有潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号